NTRA · US market
NATERA
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$58.88bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$192.35m
- Latest-quarter run-rate earnings
- -US$267.88m
- Latest fiscal-year earnings
- -US$208.16m
- Trailing revenue
- US$2.71bn
- Latest-quarter run-rate revenue
- US$3.01bn
- Latest fiscal-year revenue
- US$2.31bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- HELX · Franklin Genomic Advancements ETF7.46% weight · Holdings dated 30 June 2026
- BBH · VanEck Biotech ETF4.92% weight · Holdings dated 30 June 2026
- BOPAX · Sterling Capital Special Opportunities Fund Class A4.71% weight · Holdings dated 30 June 2026
- EKG · First Trust Nasdaq Lux Digital Health Solutions ETF4.66% weight · Holdings dated 30 June 2026
- ARKG.L · ARK Genomic Revolution UCITS ETF4.40% weight · Holdings dated 3 August 2026
- ARKG · ARK Genomic Revolution ETF4.07% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
- GNOM · Global X Genomics & Biotechnology ETF4.03% weight · Holdings dated 31 May 2026
- FBT · First Trust NYSE Arca Biotechnology Index Fund3.79% weight · Holdings dated 30 June 2026
- SAGAX · Virtus Zevenbergen Innovative Growth Stock Fund Class A3.40% weight · Holdings dated 30 June 2026
- LKSMX · LKCM Small-Mid Cap Equity Fund Institutional Class3.17% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.